Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. It focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Yield10 Bioscience, Inc. is an agricultural bioscience company, which engages in the development of oilseed Camelina sativa as a platform crop for large scale production of low carbon sustainable seed products. The company was founded by Anthony J. Sinskey, Simon F. Williams, and Oliver P. Peoples in 1992 and is headquartered in Woburn, MA.

Yield10 Bioscience and BioMar Group have signed an LOI to form a long-term partnership to commercialize a Camelina crop containing enriched levels of EPA and DHA equal to fish oil. After a decade of research, this Omega-3 Camelina technology is now advancing toward market availability and has the potential to become another important, high-quality supplement to the scarce supply of marine long-chain fatty acids.

Yield10 Bioscience and BioMar Aim to Grow Fish Oil on Land

Farmer Bros.

Red Robin

Focusing on small cap stocks and emphasizing the importance of admitting you're wrong. Farmer Brothers, Red Robin Gourmet Burgers, and Yield10 Bioscience examples of small cap stocks with potential.

Courage & Conviction Investing On Farmer Bros, Red Robin And Yield10 Bioscience

WOBURN, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company has exercised its option to finalize an exclusive global, commercial license to advanced omega-3 production technology from U.K.-based Rothamsted Research Limited (“Rothamsted”). In 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted's Flagship Program to develop omega-3 oils in Camelina sativa (“Camelina”). As part of the collaboration agreement, Yield10 received an exclusive option to sign a global, exclusive license agreement for the technology.

Yield10 Bioscience Exercises Option to Finalize an Exclusive, Global Commercial License to Advanced Omega-3 Camelina Technology from Rothamsted Research

-On track for commercial launch of first herbicide tolerant Camelina variety as early as 2025 -First field tests of stacked herbicide tolerant winter Camelina underway -Recent positive field tests demonstrate stacked herbicide traits in spring Camelina -Herbicide tolerance in Camelina supports large acreage production of low-carbon intensity feedstock oil for the biofuel market WOBURN, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced recent advancements toward enabling weed control for Camelina cultivation and supporting grower adoption of the crop for production of low-carbon intensity feedstock oil for the biofuel market.

Yield10 Bioscience Provides Update on Recent Advancements in the Development of Elite Herbicide Tolerant Camelina

Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform Begins revenue generation for “Camelina Seed Genetics to Biofuel” platform

Yield10 Bioscience Completes Harvest of a Majority of the 2023 Winter and Spring Camelina Grain Grown Under Contract, Generating Revenue from Biofuel Production

Advanced Emissions Solutions

Courage & Conviction Investing discusses why small cap investors should stay committed and have conviction in their ideas despite market drawdowns. Why he's never been more bullish on Advanced Emissions Solutions.

'Stay Hungry, Stay Foolish' Small Cap Strategies With Courage & Conviction Investing

WOBURN, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held on September 11-13, 2023, at the Lotte New York Palace Hotel.

Yield10 Bioscience to Present at the H.C. Wainwright 25th Annual Global Investment Conference

WOBURN, Mass., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the closing of its previously announced public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consisted of one share of common stock and one warrant to purchase one share of common stock. The warrants are immediately exercisable at an exercise price of $0.65 per share and expire five years from the date of issuance. The shares of common stock and accompanying warrants could only be purchased together in this offering but were issued separately and are immediately separable upon issuance.

Yield10 Bioscience Announces Closing of $3.7 Million Public Offering

Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oli Peoples – Chief Executive Officer Kristi Snell – Vice President of Research and Chief Science Officer Chuck Haaser – Chief Accounting Officer Conference Call Participants Anthony Vendetti – Maxim Group Operator Welcome to the Second Quarter 2023 Financial Results and Business Update Conference Call for Yield10 Bioscience. During the call, participants will be in a listen-only mode.

Yield10 Bioscience, Inc. (YTEN) Q2 2023 Earnings Call Transcript

-Harvesting underway for contracted winter and spring Camelina acres for the biofuels market -Reported positive results in first field tests of stacked herbicide tolerant Camelina -Filed a request for regulatory status review with USDA-APHIS for omega-3 (EPA) Camelina -Strengthened balance sheet with recent financing -Management will host a conference call today at 4:30 pm (ET)

Yield10 Bioscience Announces Second Quarter 2023 Financial Results

WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2023 financial results and provide a corporate update on Monday, August 14, 2023.

Yield10 Bioscience to Announce Second Quarter 2023 Financial Results and Host a Conference Call on Monday, August 14, 2023

WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced the pricing of its public offering of 5,750,000 units at a public offering price of $0.65 per unit. Each unit consists of one share of common stock and one warrant to purchase one share of common stock. The warrants will be immediately exercisable at an exercise price of $0.65 per share and will expire five years from the date of issuance. The shares of common stock and accompanying warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.

Yield10 Bioscience Announces Pricing of $3.7 Million Public Offering

Yield10 Bioscience (NASDAQ: YTEN ) stock is falling hard on Friday after a public share offering went into effect. The company has filed its notice of effectiveness for this share offering but hasn't provided an updated press release with the details of it.

Why is Yield10 Bioscience (YTEN) Stock Down 46% Today?

-Findings demonstrate a key advancement in the development of proprietary Camelina varieties tolerant to application of broadleaf weed control as well as to Group 2 soil residual herbicide chemistries

Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market

-Omega-3 (EPA) Camelina planted at acre-scale in US nearing maturity -Development program moving forward at a solid pace toward commercialization WOBURN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company recently filed a request for a Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (BRS) under the SECURE Rule for proprietary elite Camelina varieties containing genes enabling the plant to produce the eicosapentaenoic acid (“EPA”) component of omega-3 oil.

Yield10 Bioscience Files Request for Regulatory Status Review under USDA-APHIS's SECURE Rule Covering Elite Camelina Designed to Produce the EPA Component of Omega-3 Oil

Bone Biologics Corp

Fresh2 Group Ltd

VistaGen Therapeutics

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month - Bone Biologics (NASDAQ:BBLG), Fresh2 Group (NASDAQ:FRES)

Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Lynne Brum - Vice President of Planning and Corporate Communications Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice President of Research and Chief Science Officer Chuck Haaser - Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Anthony Vendetti - Maxim Group Sameer Joshi - H.C. Wainwright Operator Welcome to the First Quarter 2023 Financial Results and Business Update Conference Call for Yield10 Bioscience.

Yield10 Bioscience, Inc. (YTEN) Q1 2023 Earnings Call Transcript

WOBURN, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, today reported financial results for the first quarter ended March 31, 2023.

Yield10 Bioscience Announces First Quarter 2023 Financial Results

WOBURN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its first quarter 2023 financial results and provide a corporate update on Wednesday, May 10, 2023.

Yield10 Bioscience to Announce First Quarter 2023 Financial Results and Host a Conference Call on Wednesday, May 10, 2023

WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has agreed to sell $3.0 million of its shares of common stock (or prefunded warrants in lieu thereof) in a registered direct offering and warrants in a concurrent private placement with investors including a certain institutional investor and an existing investor.

Yield10 Bioscience Announces Pricing of $3.0 Million Registered Direct Offering and Concurrent Private Placement

WOBURN, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it has signed a non-binding Letter of Intent (“LOI”) with Marathon Petroleum Corp. (NYSE: MPC, “Marathon”) for a potential investment and offtake agreement for low-carbon intensity Camelina feedstock oil for use in renewable fuels production. Marathon is a leading, integrated downstream energy company in the U.S.

Yield10 Bioscience and Marathon Petroleum Corporation Sign LOI for Potential Investment and Offtake Agreement for Camelina Feedstock Oil for Renewable Fuels

Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q4 2022 Earnings Conference Call March 14, 2023 4:30 PM ET Company Participants Lynne Brum – Vice President of Planning and Corporate Communications Oliver Peoples – President and Chief Executive Officer Kristi Snell – Vice President of Research and Chief Science Officer Chuck Haaser – Chief Accounting Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Anthony Vendetti - Maxim Group Sameer Joshi - H.C. Wainwright Operator Greeting and welcome to the Fourth Quarter 2022 Financial Results and Business Update Conference Call for Yield10 Bioscience.

Yield10 Bioscience, Inc. (YTEN) Q4 2022 Earnings Call Transcript

-Executing strategy to build supply chain alliances for the production of low-carbon intensity Camelina feedstock oil for the biofuels market -Advancing development of herbicide tolerant Camelina varieties -Accelerating development of omega-3 Camelina

Yield10 Bioscience Announces Fourth Quarter and Full Year 2022 Financial Results

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its fourth quarter and full year 2022 financial results and provide a corporate update on Tuesday, March 14, 2023.

Yield10 Bioscience to Announce Fourth Quarter and Full Year 2022 Financial Results and Host a Conference Call on Tuesday, March 14, 2023

WOBURN, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that it signed a Memorandum of Understanding (“MOU”) with American Airlines, Inc. (NASDAQ: AAL) on February 27, 2023 to collaborate in developing the value chain for Camelina as a low-carbon feedstock oil for sustainable aviation fuel (“SAF”). American is committed to helping to scale SAF production as a cornerstone of its climate strategy this decade.

Yield10 Bioscience and American Airlines Sign MOU to Form a Collaboration to Develop the Value Chain for Camelina as a Feedstock Oil for Sustainable Aviation Fuel

News for Yield10 Bioscience Stock (YTEN)